BioNTech SE (BNTX) FCF Margin (2018 - 2025)

BioNTech SE (BNTX) posted FCF Margin of 41.07% for Q4 2025, down 23.6% sequentially from 53.76% in Q3 2025, and up 4109.0% YoY from 0.98% in Q4 2024.

BioNTech SE (BNTX) FCF Margin (2018 - 2025) Analysis & Trends

BioNTech SE has reported FCF Margin for 8 years, with the latest figure at 41.07% in Q4 2025.

Quarterly FCF Margin rose 4109.0% year-over-year to 41.07% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 24.56% (up 2454.0% YoY) and the FY2025 annual result came in at 9.79%, up 1265.0% from the prior year.
FCF Margin declined to 41.07% in Q4 2025 per BNTX's latest filing, from 53.76% in the prior quarter.
Over five years, FCF Margin peaked at 2655.87% in Q2 2023 and troughed at 400.33% in Q1 2025.
A 5-year average of 203.08% and a median of 33.59% in 2021 frame the typical range for FCF Margin.
The sharpest annual moves came in 2023 and 2024: FCF Margin soared 253106 bps in 2023, then plunged 132270 bps in 2024.
Over 5 years, FCF Margin stood at 4.32% in 2021, then soared by 423 bps to 22.57% in 2022, then surged by 180 bps to 63.2% in 2023, then tumbled by 100 bps to 0.01% in 2024, then jumped by 341774 bps to 41.07% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 41.07%, 53.76%, and 66.56% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	BioNTech SE	23.54 Bn	5.15 Bn	668.28 Mn	41.07%

Download Data